The European Medicines Agency (EMA) will move from London to Amsterdam (The Netherlands) by March 2019. The EMA is the EU agency in charge of medicines evaluation and safety monitoring. The relocation site was voted on Monday 20th November in the margins of the General Affairs Council, as a result of the activation of Article 50 of the EU treaty by the United Kingdom, who will leave the European Union.
EFA is glad that patients’ concerns have been taken into account for the relocation of EMA. This agency is crucial for the life of European patients, not only because of their mandate to evaluate on new and safety monitoring of existing medicines, but also because of their close collaboration with patient and consumer groups as official stakeholders. EFA is an eligible organisation and member of the Patients and Consumers Working Party, as well as a trusted advisor for the information to patients, scientific advice and evaluation processes on medicines in all of our disease areas.
More information on the work of EFA and patient organisations with EMA here
EFA’s involvement in EMA’s activities: http://www.efanet.org/resources/library/3164-efa-s-involvement-in-european-medicines-agency-processes-since-january